New antibody drug aims to halt Scleroderma's grip
NCT ID NCT05726630
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 3 trial tests whether the drug divozilimab can reduce skin thickening and protect lung function in people with systemic scleroderma, a rare autoimmune disease. About 152 adults and teens with active disease will receive either the drug or a placebo. The study is double-blind, meaning neither patients nor doctors know who gets what.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Divozilimab (a lab-made antibody that targets certain immune cells)
What this could lead to
If it works, this could offer a new treatment option to slow skin hardening and preserve lung function in people with systemic scleroderma.
What could go wrong
This is a Phase 3 trial, but results are not yet known. The drug may not improve symptoms better than placebo, and side effects from immune suppression are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC SCLERODERMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Chelyabinsk Regional Clinical hospital
Chelyabinsk, Russia
-
Clinical Rheumatology Hospital №25
Saint Petersburg, Russia
-
North-Western state Medical University named after I.I. Mechnikov
Saint Petersburg, Russia